11/11 (100%) and 0/1 (0%) of those having been treated with RTX and BTKi, respectively, were in remission

11/11 (100%) and 0/1 (0%) of those having been treated with RTX and BTKi, respectively, were in remission. of practice. HMGIC IgA was further less responsive (unsuccessful seroconversion in 11/12 (92%)), implicating an underlying class switch defect. Those with depletion on B-cells are caught at a dilemma between, being too early and too late on receiving SARS-CoV-2 vaccines. They wish to get over their immunological na?vety at the earliest, while, in order to assure quality immune memory, are also required to hold the patience for their B-cells to repopulate. Although it remains an issue whether intensified vaccine schedules and/or regimens will lead to stronger immunogenicity or more effective boosters for non-responders, we shall take advantage of every increasing evidence in order to optimize current options. Keywords: SARS-CoV-2 vaccine, Antibody response, Lymphoid malignancy, Rituximab SARS-CoV-2 vaccines having aided in escaping the majority of the population from immunological na?vety, our strategies against the pandemic are now shifting towards an increased focus on identifying and protecting the persistently vulnerable. The increased risk of morbimortality against COVID-19 in patients with hematological malignancies, having been observed ever since the beginning of the pandemic [1], seemingly extends beyond the completion of the scheduled vaccine doses [2]. The population has been given highest priority in the Japanese national SARS-CoV-2 vaccination campaign, while their immunological response to the initial vaccine doses has been less intensely studied. We thus planned to prospectively monitor the vaccine’s immunogenicity in patients with lymphoid malignancies with specific focus on those receiving B-cell-directed therapy for treatment. The study was approved by the Osaka Metropolitan University Institutional Ethics Committee (#2020C101) and performed upon written consent from the participants. Participants provided sera for anti-SARS-CoV-2 serological testing at median 2.0 (range 1.1C4.7) months after the second scheduled Pfizer-BioNTech BNT162b2 mRNA vaccine dose. Clinical variables, regarding the diagnosis of underlying malignancy, treatment regimen, its timing, disease status, absolute lymphocyte count before the first dose of vaccination, and the dates of the two scheduled vaccine doses were recorded. Anti-spike IgG and IgA antibody titers were measured with the Abbott Architect SARS-CoV-2 IgG II Quant (Chicago, IL, USA) and EUROIMMUN Picaridin anti-SARS-CoV-2 Picaridin ELISA IgA (EUROIMMUN Medizinische Labordiagnostika AG, Lbeck, Germany) immunoassays, respectively. Rates of achieving seroconversion and seroprotection were assessed. Successful seroconversion was defined as a titer 50 [AU/mL] for anti-spike IgG, and a titer 1.1 [S/C ratio] for anti-spike IgA according to the manufacturers’ definitions. Extrapolating from a previous clinical trial estimating the 90%-efficacy antibody titer in preventing symptomatic COVID-19 [3], the seroprotection threshold was defined as a post-vaccine IgG Picaridin antibody titer of 775 [BAU/mL] in the WHO standard unit, equivalent to 5458 [AU/mL] (derived from division with the assay-specific conversion factor of 0.142). Comparisons of titer used the Mann-Whitney test and two-sided p-values < 0.05 were considered significant. Twelve patients (8/12 were male), aged at median 71.5 (range 41C88) years old and having received B-cell-directed therapy for their treatment of lymphoma/leukemia (11 with rituximab-containing regimens (RTX); 1 with Bruton tyrosine kinase inhibitor (BTKi)) at the National Cancer Center Hospital East, Kashiwa, Japan, composed the RTX/BTKi group. 11/11 (100%) and 0/1 (0%) of those having been treated with RTX and BTKi, respectively, were in remission. All participants were seronegative against SARS-CoV-2 upon entry and were monitored of their humoral immune response to the scheduled two doses of the BNT162b2 mRNA vaccine. Patients of the RTX/BTKi group exhibited significantly attenuated anti-spike antibody responses compared with vaccine recipients with other lymphoid malignancies (Other group, n?=?5; one each with multiple myeloma, myeloproliferative neoplasm, myeloid sarcoma, anaplastic large cell lymphoma, and peripheral T-cell lymphoma) visiting the department (3/5 were male; aged at median 50 years old, range 29C59) (Fig. 1 ). Between the RTX/BTKi and Other groups, there was a surprising 280-fold difference in their anti-spike IgG geometric mean titer [95% confidence interval] (10.3 [1.1C93.2] vs. 2889 [790C10570] AU/mL, p?=?0.0013). Successful IgG seroconversion was achieved in 4/12 (33%) of the patients with B-cell malignancies on RTX/BTKi, supporting the overall benefit of vaccination. However, their rate of seroconversion was relatively low compared with 5/5 (100%) in the Other group. More importantly, seroprotection was achieved in 0/12 (0%) participants from the RTX/BTKi group, while 1/5 (20%) from the Other group achieved seroprotection. In a recent study from Japan targeting the healthy population, 67% were seroprotected after.